Clinical Trials

Steve Braunstein, MD, PhD

Ride to care

Eliminating transportation barriers for disadvantaged cancer patients undergoing RT

Catherine Park, MD

FABREC

Study of Radiation Fractionation on Patient Outcomes After Breast Reconstruction for Invasive Breast Carcinoma

Anthony Wong, MD, PhD

FORMULA-509

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management

Anthony Wong, MD, PhD

RTOG 3506

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

Osama Mohamad, MD, PhD

GU 008

Randomized Phase III Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy

Sue Yom, MD, PHD

NRG-HN001

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).

Sue Yom, MD, PhD

Nivolumab +  ChemoRT for Patients with Nasopharyngeal Cancer

Sue Yom, MD, PhD

A Phase 1/2 Trial of Concurrent RT, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Sue Yom, MD, PhD

HN004

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Sue Yom, MD, PhD

HN005

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Sue Yom, MD, PhD

PembroX

Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study with Correlative Biomarkers

Steve Braunstein, MD, PhD

METIS

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Sue Yom, MD, PhD

RTOG 1216

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Mary Feng, MD

ARM-GI

Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy

Mary Feng, MD

Phase II Trial

Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Progression on Prior PD-1 Inhibition

Mary Feng, MD

DECREASE

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma